161 related articles for article (PubMed ID: 37866028)
1. Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial.
Brighi N; Conteduca V; Gurioli G; Scarpi E; Cursano MC; Bleve S; Lolli C; Schepisi G; Casadei C; Gianni C; Ulivi P; De Giorgi U
ESMO Open; 2023 Dec; 8(6):102036. PubMed ID: 37866028
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G; Conteduca V; Brighi N; Scarpi E; Basso U; Fornarini G; Mosca A; Nicodemo M; Banna GL; Lolli C; Schepisi G; Ravaglia G; Bondi I; Ulivi P; De Giorgi U
BMC Med; 2022 Jan; 20(1):48. PubMed ID: 35101049
[TBL] [Abstract][Full Text] [Related]
3. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
4. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
5. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Conteduca V; Castro E; Wetterskog D; Scarpi E; Jayaram A; Romero-Laorden N; Olmos D; Gurioli G; Lolli C; Sáez MI; Puente J; Schepisi G; Salvi S; Wingate A; Medina A; Querol-Niñerola R; Marin-Aguilera M; Arranz JA; Fornarini G; Basso U; Mellado B; Gonzalez-Billalabeitia E; Attard G; De Giorgi U
Eur J Cancer; 2019 Jul; 116():158-168. PubMed ID: 31200322
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
7. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca V; Wetterskog D; Castro E; Scarpi E; Romero-Laorden N; Gurioli G; Jayaram A; Lolli C; Schepisi G; Wingate A; Casadei C; Lozano R; Brighi N; Aragón IM; Marin-Aguilera M; Gonzalez-Billalabeitia E; Mellado B; Olmos D; Attard G; De Giorgi U
Eur J Cancer; 2021 Jul; 152():49-59. PubMed ID: 34077818
[TBL] [Abstract][Full Text] [Related]
8. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Salvi S; Casadio V; Conteduca V; Lolli C; Gurioli G; Martignano F; Schepisi G; Testoni S; Scarpi E; Amadori D; Calistri D; Attard G; De Giorgi U
Oncotarget; 2016 Jun; 7(25):37839-37845. PubMed ID: 27191887
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
10. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V; Scarpi E; Caroli P; Salvi S; Lolli C; Burgio SL; Menna C; Schepisi G; Testoni S; Gurioli G; Paganelli G; Casadio V; Matteucci F; De Giorgi U
Sci Rep; 2017 Nov; 7(1):15541. PubMed ID: 29138500
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
12. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
Del Re M; Conteduca V; Crucitta S; Gurioli G; Casadei C; Restante G; Schepisi G; Lolli C; Cucchiara F; Danesi R; De Giorgi U
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):524-531. PubMed ID: 33500577
[TBL] [Abstract][Full Text] [Related]
14. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
15. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
16. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction.
Buelens S; Claeys T; Dhondt B; Poelaert F; Vynck M; Yigit N; Thas O; Ost P; Vandesompele J; Lumen N; Kumps C
Clin Genitourin Cancer; 2018 Jun; 16(3):197-205.e5. PubMed ID: 29366632
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
19. Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.
Cursano MC; Conteduca V; Scarpi E; Gurioli G; Casadei C; Gargiulo S; Altavilla A; Lolli C; Vincenzi B; Tonini G; Santini D; De Giorgi U
Sci Rep; 2022 May; 12(1):7319. PubMed ID: 35513478
[TBL] [Abstract][Full Text] [Related]
20. Plasma
Gurioli G; Conteduca V; Lolli C; Schepisi G; Gargiulo S; Altavilla A; Casadei C; Scarpi E; De Giorgi U
Front Oncol; 2020; 10():567809. PubMed ID: 33072600
[No Abstract] [Full Text] [Related]
[Next] [New Search]